Cystic Fibrosis Therapeutics in Major Developed Markets Cystic Fibrosis Therapeutics in Major Developed Ma | Page 3

4 Developmental Pipeline 25
4.1 Overview 25
4.2 Mechanisms of Action in the Pipeline 27
4.3 Clinical Trials 30
4.3.1 Failure Rate 30
4.3.2 Clinical Trial Duration 31
4.3.3 Clinical Trial Size 32
4.4 Promising Pipeline Molecules 35
4.4.1 Lumacaftor (VX809) - Vertex Pharmaceuticals 35
4.4.2 Ataluren (P